Harvard doctors will now be limited to making $5,000 a year for serving as board members for drugmakers and biotech companies, under a new rule intended to reduce the conflicts of interest in medical research.
Scott Hensley explains and rounds up the coverage on NPR’s Shots blog, with links to stories in The New York Times and The Boston Globe. Hensley writes that the new rules also prohibit taking company shares as compensation and from serving on drug companies’ speaker bureaus.
